nileprost | 85505-32-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: nileprost
• 英文别名: (5E)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S,4S)-3-hydroxy-4-methyloct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]-5-cyanopentanoic acid
• CAS: 85505-32-4
• 化学式: C₂₂H₃₃NO₅
• 分子量: 391.508
• InChiKey: OJIGXQJDLFUVFM-AGCJUELTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  28
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  111
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
  申请人：deLong A. Mitchell

  公开号：US20070254920A1

  公开（公告）日：2007-11-01

  This invention relates to novel homotopic prodrugs and medicaments and methods for their preparation, testing and use. In one embodiment, the homotopic prodrug has the general formula wherein is a biologically-active moiety comprising a carboxylic acid functional group, and R b is a homotopically-symmetrical alcohol bonded to the biologically-active moiety through the carboxylic acid functional group to form an ester linkage, as well as optical isomers, enantiomers, pharmaceutically acceptable salts, biohydrolyzable amides, esters, and imides thereof and combinations thereof.

  这项发明涉及新型同位素前药、药物以及其制备、测试和使用方法。在一个实施例中，同位素前药具有一般公式 其中 是包含羧酸官能团的生物活性基团，而 R b 是通过羧酸官能团与生物活性基团形成酯键的同位对称醇，以及其光学异构体、对映异构体、药用可接受盐、生物水解酰胺、酯、亚酰胺及其组合物。
• Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
  申请人：Price John D.

  公开号：US10150792B2

  公开（公告）日：2018-12-11

  Bismuth-containing compounds include bismuth and a biologically active agent coordinated to the bismuth. The biologically active agent includes at least one heteroatom configured for coordination with the bismuth. Coordination polymers include a polymer matrix that contains a bismuth-containing compound. Methods for modulating a pharmacokinetic property of a biologically active agent include coordinating the biologically active agent to bismuth to form a bismuth-containing compound, and administering the bismuth-containing compound orally to a patient. Methods for treating Parkinson's disease, methods for treating hypothyroidism, methods for treating ulcerative colitis, and methods for treating cancer each include administering a bismuth-containing compound to a patient.

  含铋化合物包括铋和与铋配位的生物活性剂。生物活性剂包括至少一个用于与铋配位的杂原子。配位聚合物包括包含含铋化合物的聚合物基质。调节生物活性剂的药代动力学特性的方法包括将生物活性剂与铋配位形成含铋化合物，并将含铋化合物口服给患者。治疗帕金森病的方法，治疗甲状腺功能减退症的方法，治疗溃疡性结肠炎的方法，以及治疗癌症的方法各自包括向患者口服含铋化合物。
• Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
  申请人：——

  公开号：US20030130246A1

  公开（公告）日：2003-07-10

  Disclosed are compounds that exhibit high transport across the intestinal wall of an animal. The compounds may optionally be linked to drugs that are poorly absorbed or poorly transported across the intestinal wall after oral administration to provide for enhanced therapeutic, and optionally prolonged therapeutic, systemic blood concentrations of the drugs upon oral administration of the drug-compound conjugate. Also disclosed are pharmaceutical compositions containing and methods of using such compounds.

  本文披露了一种在动物肠壁上具有高透过性的化合物。这些化合物可以选择性地与那些口服后吸收或透过肠壁运输效果不佳的药物结合，以提高药物-化合物共轭物口服后的治疗效果，并在口服药物-化合物共轭物时实现药物在全身血液中的浓度增加，可选择性地延长药物的治疗效果。还披露了含有这些化合物的药物组合物及使用这些化合物的方法。
• Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
  申请人：——

  公开号：US20030171303A1

  公开（公告）日：2003-09-11

  The present invention provides a method for synthesizing 1-(acyloxy)-alkyl derivatives from 1-acyl-alkyl derivatives, which typically proceeds stereospecifically, in high yield, does not require the use of activated intermediates and/or toxic compounds and is readily amenable to scale-up. The current invention also provides 1-acyl-alkyl derivatives of known drug compounds and methods for synthesizing these 1-acyl-alkyl derivatives.

  本发明提供了一种从1-酰基-烷基衍生物合成1-(酰氧基)-烷基衍生物的方法，该方法通常具有立体特异性，产率高，不需要使用活化中间体和/或有毒化合物，并且易于扩大生产规模。本发明还提供了已知药物化合物的1-酰基-烷基衍生物以及合成这些1-酰基-烷基衍生物的方法。
• Novel 5-cyano-prostacyclin derivatives and their use as agents for the treatment of influenza a viral infection
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP1975163A1

  公开（公告）日：2008-10-01

  This invention is directed to compounds of formula (I): where A, B, D, E, m, and R1 - R5 are as described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, clathrates, or prodrugs thereof, which compounds are useful in treating respiratory diseases associated with influenza A viruses, such as for example H5N1 and its mutations. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

  本发明涉及以下式(I)的化合物：其中A、B、D、E、m和R1 - R5如本文所述，可以是单个立体异构体或立体异构体混合物，或其药学上可接受的盐、包合物或前药，这些化合物在治疗与流感A病毒相关的呼吸道疾病方面有用，例如H5N1及其突变体。还公开了包含本发明化合物的药物组合物和制备本发明化合物的方法。